[Considerations on 30 patients treated with sulpiride].
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D001321:Autistic Disorder / Q000188:drug therapy; D001565:Benzoates / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy; D002389:Catatonia / Q000188:drug therapy; D003693:Delirium / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D004357:Drug Synergism; D006801:Humans; D006998:Hypochondriasis / Q000188:drug therapy; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy; D011602:Psychophysiologic Disorders / Q000188:drug therapy; D011759:Pyrrolidines / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy; D013449:Sulfonamides / Q000627:therapeutic use*; D013451:Sulfonic Acids / Q000009:adverse effects; D014149:Tranquilizing Agents / Q000627:therapeutic use
D000928:Antidepressive Agents; D001565:Benzoates; D011759:Pyrrolidines; D013449:Sulfonamides; D013451:Sulfonic Acids; D014149:Tranquilizing Agents
Considérations ur trente malades traités par le sulpiride.